首次人体(FTIH)研究:调查GSK5533524单药或联合用药在晚期实体瘤成年参与者中的安全性和初步活性
一项针对选定晚期实体瘤成年受试者的 GSK5533524 单药或与其他抗癌药物联合用药的 1 期、开放标签、多中心研究
The purpose of this study is to investigate a new drug GSK5533524 in adults with certain advanced cancers to find a safe dose and learn how well people tolerate it, so researchers can choose the best dose for the next stage of testing. The study will also check whether the drug can shrink tumours or slow cancer growth, monitor how the body absorbs and breaks down the drug, and look for any immune reactions that the body might develop against the treatment.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
研究联系人备份
- 姓名:EU GSK Clinical Trials Call Center
- 电话号码:+44 (0) 20 89904466
- 邮箱:GSKClinicalSupportHD@gsk.com
学习地点
-
-
Capital Region
-
København Ø、Capital Region、丹麦、2100
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Lise Omland
-
-
-
-
Ontario
-
Toronto、Ontario、加拿大、M5G 2M9
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Stephanie Lheureux
-
-
Quebec
-
Montreal、Quebec、加拿大、H3T 1E2
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- susie lau
-
Montreal、Quebec、加拿大、H2X 0A9
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Diane Provencher
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
-
-
-
-
Saitama、日本、350-1298
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Kosei Hasegawa
-
Shizuoka、日本、411-8777
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Akiko Furusawa
-
Tokyo、日本、104-0045
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Kan Yonemori
-
Tokyo、日本、135-8550
- 招聘中
- GSK Investigational Site
-
首席研究员:
- Shigehisa Kitano
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
-
-
-
-
Bordeaux、法国、33076
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Coriolan Lebreton
-
Villejuif、法国、94805
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Kaissa Ouali
-
-
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19107-4330
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Ida Micaily
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
-
Texas
-
San Antonio、Texas、美国、78229-3307
- 招聘中
- GSK Investigational Site
-
首席研究员:
- Drew Rasco
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
-
-
-
-
Helsinki、芬兰、00029
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Katriina Jalkanen
-
-
-
-
-
Cambridge、英国、CB2 2QQ
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Joo Ern Ang
-
Edinburgh、英国、EH4 2XU
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Charlie Gourley
-
-
-
-
-
Barcelona、西班牙、08035
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Elena Garralda Cabanas
-
Madrid、西班牙、28009
- 招聘中
- GSK Investigational Site
-
首席研究员:
- Ana Oaknin
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
Madrid、西班牙、28027
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Antonio González Martín
-
Madrid、西班牙、28041
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Ainhoa Madariaga Urrutia
-
Madrid、西班牙、28050
- 招聘中
- GSK Investigational Site
-
首席研究员:
- Emiliano Calvo Aller
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Is at least 18 years of age or the legal age of consent
- Has histologically or cytologically confirmed advanced/metastatic solid tumor that is refractory or intolerant to standard therapy, has exhausted all treatment options and is not considered a candidate for definitive radiotherapy.
- Has documented disease progression based on radiologic imaging, during or after most recent line of treatment.
- Has at least one target lesion per RECIST 1.1.
- Has an Eastern Cooperative Oncology Group performance status of 0 or 1 and no deterioration in the 2 weeks before enrollment.
- Has adequate organ function.
- Has a life expectancy of at least 3 months.
Exclusion Criteria:
- Has a history of clinically significant or uncontrolled cardiac disease, acute myocardial infarction, congestive heart failure or clinically significant arrhythmia not controlled by Standard of care therapy.
- Presence of pleural/abdominal effusion/ascites requiring clinical intervention; presence of pericardial effusion.
- Has untreated brain or central nervous system metastases or metastases that have progressed
- Has a Grade ≥2 corneal epithelial condition.
- Has any active renal condition
- Has a history of autoimmune disease that has required systemic treatments in the 2 years prior to screening.
- Has ongoing adverse reaction(s) from prior therapy that has(have) not recovered to ≤Grade 1 or to the baseline status preceding prior therapy.
- Has a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis, or current ILD/pneumonitis.
- Has a lung-specific intercurrent clinically significant illness
- Has FEV1 <50% predicted
- Has chronic enteritis or inflammatory bowel disease or any history of clinically significant bleeding of gastrointestinal tract or clinically significant obstruction and/or perforation and/or fistulae of GI tract.
- Has a known hypersensitivity to any component of GSK5533524 or its excipients.
- Has history of severe allergies, or severe infusion related reactions, or idiosyncrasy to recombinant humanized proteins.
- Has received any cytotoxic chemotherapy drugs, or other anti-tumor drugs within 28 days prior to the first dose of study drug.
- Has received radiotherapy to the lungs, or to adjacent organs, within 6 months prior to the first dose of study intervention; locoregional radiation therapy within 2 weeks prior to the first dose of study drug; more than 30% of bone marrow irradiation or wide-field radiation therapy within 4 weeks prior to the first dose of study intervention.
- Has received immunosuppressive agents or required long-term glucocorticoid therapy within 30 days prior to first dose of study treatment.
- The use of concomitant medications known to prolong the QT/QTc interval or potentially cause torsades de pointes.
- Has corrected QT interval by Fridericia formula (QTcF) >470 msec or QTcF >480 msec for participants with bundle branch block.
- Has a left ventricular ejection fraction (LVEF) < 50%.
- Has risk factors for prolonged QT/QTc or TdP, such as heart failure, refractory hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death of any direct relative under 40 years old.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:第1b部分:GSK5533524剂量扩展
|
GSK5533524 will be administered. |
|
实验性的:Part 1a: GSK5533524 Dose Escalation
|
GSK5533524 will be administered. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
第1a部分:每个剂量水平出现剂量限制性毒性(DLT)的参与者数量
大体时间:最多21天
|
最多21天
|
|
|
第1a部分:按剂量级别严重程度划分的参与者不良事件(AEs)和严重不良事件(SAEs)数量
大体时间:最长约34个月
|
最长约34个月
|
|
|
Part 1b: Objective Response Rate (ORR)
大体时间:Up to approximately 27 months
|
ORR is defined as the proportion of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). |
Up to approximately 27 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
第1a及1b部分:按严重程度分类的不良事件(AEs)、严重不良事件(SAEs)、治疗期间出现的不良事件(TEAEs)、特别关注不良事件(AESIs)的参与者数量,以及导致剂量调整和治疗终止的不良事件
大体时间:长达约34个月
|
长达约34个月
|
|
|
第 1a 和 1b 部分:GSK5533524 及其成分的药代动力学 (PK) 浓度
大体时间:最长约27个月
|
最长约27个月
|
|
|
第1a和1b部分:产生针对GSK5533524抗药物抗体(ADA)的参与者数量
大体时间:最长约27个月
|
最长约27个月
|
|
|
第1a和1b部分:抗GSK5533524的ADA滴度
大体时间:最长约27个月
|
最长约27个月
|
|
|
Part 1a: Objective Response Rate (ORR)
大体时间:Up to approximately 27 months
|
ORR is the proportion of participants with a BOR of CR or PR as assessed by the investigator according to RECIST 1.1. |
Up to approximately 27 months
|
|
Part 1a & 1b: Duration of Response (DoR)
大体时间:Up to approximately 27 months
|
DoR is evaluated in participants who achieve a CR or PR, based on investigator assessment per RECIST 1.1. |
Up to approximately 27 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- 300163
- 2025-524165-25 (其他标识符:EU CT Number)
- 2025 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf
IPD 共享时间框架
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
IPD 共享访问标准
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.
IPD 共享支持信息类型
- 研究方案
- 树液
- 国际碳纤维联合会
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.